阿达木单抗（修美乐®）在接受三种不同抗 TNF 疗法的患者中诱发复发性扁桃体周脓肿：一例报告
Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report.
作者信息
Vural Sevilay, Kuşdoğan Mikail, Kaya Hasan Burak, İkiz Venhar, Albayrak Levent
机构信息
Department of Emergency Medicine, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Department of Emergency Medicine, Yozgat Bozok University, Yozgat, Turkey.
出版信息
Indian J Otolaryngol Head Neck Surg. 2023 Jun;75(2):1013-1015. doi: 10.1007/s12070-022-03203-0. Epub 2022 Dec 6.
Abstract
Anti-tumor necrosis factor agents are widely used in treating ankylosing spondylitis, but they increase the risk of infection by suppressing the immune response. Therefore, physicians should be careful about recurrent infections in patients under anti-tumor necrosis factor agents.
摘要
抗肿瘤坏死因子药物被广泛用于治疗强直性脊柱炎，但它们会通过抑制免疫反应增加感染风险。因此，医生应对接受抗肿瘤坏死因子药物治疗的患者的反复感染保持警惕。
相似文献
1
Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report.
Indian J Otolaryngol Head Neck Surg. 2023 Jun;75(2):1013-1015. doi: 10.1007/s12070-022-03203-0. Epub 2022 Dec 6.
2
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
3
Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Curr Med Res Opin. 2014 Dec;30(12):2515-21. doi: 10.1185/03007995.2014.969368. Epub 2014 Oct 8.
4
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
J Manag Care Pharm. 2013 Oct;19(8):621-30. doi: 10.18553/jmcp.2013.19.8.621.
5
Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
Int J Clin Pharm. 2015 Oct;37(5):808-14. doi: 10.1007/s11096-015-0124-1. Epub 2015 Apr 25.
6
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.
7
Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
Curr Opin Rheumatol. 2003 Jul;15(4):394-407. doi: 10.1097/00002281-200307000-00005.
8
Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Int J Rheum Dis. 2014 Mar;17(3):291-8. doi: 10.1111/1756-185X.12188. Epub 2013 Oct 16.
9
Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.
10
The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
Int J Clin Pharmacol Ther. 2012 Dec;50(12):867-72. doi: 10.5414/CP201707.
引用本文的文献
1
Sepsis: the evolution of molecular pathogenesis concepts and clinical management.
MedComm (2020). 2025 Feb 23;6(3):e70109. doi: 10.1002/mco2.70109. eCollection 2025 Mar.
2
Prostatic Abscesses in a Patient Receiving Tumor Necrosis Factor-Alpha Inhibitor Therapy for Hidradenitis Suppurativa: A Case Report.
Cureus. 2023 Jul 13;15(7):e41820. doi: 10.7759/cureus.41820. eCollection 2023 Jul.
本文引用的文献
1
Implication of Fusobacterium necrophorum in recurrence of peritonsillar abscess.
Laryngoscope. 2019 Jul;129(7):1567-1571. doi: 10.1002/lary.27675. Epub 2018 Dec 24.
2
Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials.
Exp Ther Med. 2017 Oct;14(4):3491-3500. doi: 10.3892/etm.2017.5003. Epub 2017 Aug 22.
3
Bacteriology of peritonsillar abscess: the changing trend and predisposing factors.
Braz J Otorhinolaryngol. 2018 Sep-Oct;84(5):532-539. doi: 10.1016/j.bjorl.2017.06.007. Epub 2017 Jul 17.
4
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783.
5
Epidemiology, clinical history and microbiology of peritonsillar abscess.
Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):549-54. doi: 10.1007/s10096-014-2260-2. Epub 2014 Oct 17.
6
The impact of prior tonsillitis and treatment modality on the recurrence of peritonsillar abscess: a nationwide cohort study.
PLoS One. 2014 Oct 7;9(10):e109887. doi: 10.1371/journal.pone.0109887. eCollection 2014.
7
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
Rheumatology (Oxford). 2011 Jan;50(1):124-31. doi: 10.1093/rheumatology/keq242. Epub 2010 Jul 31.
8
Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
Curr Opin Rheumatol. 2010 Jul;22(4):388-92. doi: 10.1097/BOR.0b013e32833aaf93.
9
Peritonsillar abscess: repeated needle aspiration versus incision and drainage.
Ann Otol Rhinol Laryngol. 1994 Jul;103(7):554-7. doi: 10.1177/000348949410300709.
Zotero 插件